Anixa Biosciences (ANIX) vs Black Diamond Therapeutics (BDTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anixa Biosciences (ANIX) has outperformed Black Diamond Therapeutics (BDTX) over the past year, losing 34.5% versus a loss of 54.6%. Over five years, ANIX leads with a -33.7% price change compared with -77.9% for BDTX. Black Diamond Therapeutics is the larger company by market cap ($103.7 million vs $101.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | BDTX |
|---|---|---|
| Share price | $2.91 | $1.81 |
| Market cap | $101.16M | $103.72M |
| 1-day change | -1.36% | -1.09% |
| YTD return | -6.73% | -25.51% |
| 1-year return | -34.46% | -54.64% |
| 5-year return | -33.71% | -77.87% |
| EPS (TTM) | $-0.32 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $4.94 |
| 52-week low | $2.32 | $1.60 |
| Distance from 52-week high | -46.70% | -63.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +235.05% | +452.49% |
| Average volume | 302.95K | 624.32K |
| Shares outstanding | 34.76M | 57.30M |
| Employees | 4 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIX has outperformed BDTX by 20.2 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Healthcare · Biotechnology · 4 employees
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Healthcare · Biotechnology · 21 employees
ANIX vs BDTX FAQ
Which is bigger, Anixa Biosciences or Black Diamond Therapeutics?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $103.72M compared with $101.16M for Anixa Biosciences (ANIX).
Which stock has performed better over the past year, ANIX or BDTX?
ANIX returned -34.46% over the past 12 months, compared with -54.64% for BDTX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Black Diamond Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.